1Ferri CP, Prince M, Brayne C, et al, Alzheimer' s Disease Internation- al Global prevalence of dementia : a Delphi consensus study. Lancet, 2005,366 (9503) :2112-2117.
3Serge Gauthier, Barry Reisberg, Michael Zaudig, et al. Mild cognitive impairment. Lancet, 2006,367 : 1262 - 1270.
4Boyle PA, Wilson RS, Aggarwal NT, et al. Mild cognitive impairment : risk of Alzheimer disease and rate of cognitve decline. Neurology ,2006,67:441- 445.
5Ana-Marla Simon, Lucio Schiapparelli, Pablo Salazar-Colocho, et al. Overexpression of wild-type human APP in mice causes cognitive def- icits and pathological features unrelated to Aβ levels. Neurobiology of Disease ,2009,33 : 369-378.
6Hellstrom-Lindahl E, Viitanen M, Marutle A, et al. Comparison of Ab levels in the brain of familial and sporadic Alzheimer" s disease. Neurochem Int, 2009, doi : 10. 1016/j. neuint. 2009.03. 007.
7Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent chan- ges in brain,CSF,and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer' s disease. J Neurosci ,2001, 21:372-381.
8Zhang X, Luhrs KJ, Ryff KA, et al. Suppression of nuclear transcrip- tion factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PSI dE9 mice. Neuroscience,2009, doi : 10. 1016/j. neuro- science. 2009.03. 010.
9Sunderland T, Linker G, Mirza N, et al. Decreased betaamyloidl-42 and increased tau levels in eerebrospinal fluid of patients with Alzheimer disease. JAMA ,2003 ,289 :2094-2103.
10Schoonenboom NS, Pijnenburg YA, Mulder C,et al. Amyloid beta( 1- 42 ) and phosphorylated tan in CSF as markers for early-onset Alzheimet disease. Neurology,2004,62 : 1580-1584.
